DOCSLIB.ORG

Atlas Journal

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Atlas Journal Atlas of Genetics and Cytogenetics in Oncology and Haematology Home Genes Leukemias Tumors Cancer prone Deep Insight Case Reports Portal Journals Teaching X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA Atlas Journal Atlas Journal versus Atlas Database: the accumulation of the issues of the Journal constitutes the body of the Database/Text-Book. TABLE OF CONTENTS Volume 11, Number 4, Oct-Dec 2007 Previous Issue / Next Issue Genes WWOX (16q23.1). Teresa Druck, Hoda Hagrass, Kay Huebner. Atlas Genet Cytogenet Oncol Haematol 2007; Vol 11: 499-506. [Full Text] [PDF] URL : http://atlasgeneticsoncology.org/Genes/WWOXID508ch16q23.html VRK1 (14q32.2). Pedro A. Lazo, Francisco M. Vega, Ana Sevilla, Alberto Valbuena, Marta Sanz-Garcia, Inmaculada Lopez-Sanchez, Sandra Blanco. Atlas Genet Cytogenet Oncol Haematol 2007; Vol 11: 507-514. [Full Text] [PDF] URL : http://atlasgeneticsoncology.org/Genes/VRK1ID43556ch14q32.html SPINK7 (5q33.1). Xiying Yu, Shih-Hsin Lu. Atlas Genet Cytogenet Oncol Haematol 2007; Vol 11: 515-519. [Full Text] [PDF] URL : http://atlasgeneticsoncology.org/Genes/SPINK7ID40396ch5q33.html PPM1D (17q23). Dmitry Bulavin, Oleg Demidov. Atlas Genet Cytogenet Oncol Haematol 2007; Vol 11: 520-525. [Full Text] [PDF] URL : http://atlasgeneticsoncology.org/Genes/PPM1DID41803ch17q23.html P53; TP53 (17p13) - updated. Magali Olivier. Atlas Genet Cytogenet Oncol Haematol 2007; Vol 11: 526-535. [Full Text] [PDF] URL : http://atlasgeneticsoncology.org/Genes/P53ID88.html LOXL4 (10q24.2). Kornelia Molnarne Szauter, Tibor Gorogh, Katalin Csiszar. Atlas Genet Cytogenet Oncol Haematol 2007; Vol 11: 536-541. [Full Text] [PDF] URL : http://atlasgeneticsoncology.org/Genes/LOXL4ID41193ch10q24.html Atlas Genet Cytogenet Oncol Haematol 2007; 4 I ITK (5q33.3). Berthold Streubel. Atlas Genet Cytogenet Oncol Haematol 2007; Vol 11: 542-546. [Full Text] [PDF] URL : http://atlasgeneticsoncology.org/Genes/ITKID43329ch5q33.html.html IKZF2 (2q34). Rupa Sridharan, Stephen Smale. Atlas Genet Cytogenet Oncol Haematol 2007; Vol 11: 547-551. [Full Text] [PDF] URL : http://atlasgeneticsoncology.org/Genes/IKZF2ID42885ch2q34.html EBAG9 (8q23.2). Ahmad Faried, Leri S. Faried. Atlas Genet Cytogenet Oncol Haematol 2007; Vol 11: 552-556. [Full Text] [PDF] URL : http://atlasgeneticsoncology.org/Genes/EBAG9ID40393ch8q23.html DKK1 (10q11.2). Oscar Aguilera, Alberto Munoz. Atlas Genet Cytogenet Oncol Haematol 2007; Vol 11: 557-562. [Full Text] [PDF] URL : http://atlasgeneticsoncology.org/Genes/DKK1ID44007ch10q11.html AKAP9 (7q21.2). Raffaele Ciampi, Yuri E Nikiforov. Atlas Genet Cytogenet Oncol Haematol 2007; Vol 11: 563-566. [Full Text] [PDF] URL : http://atlasgeneticsoncology.org/Genes/AKAP9ID42999ch7q21.html S100B (21q22.3). M Rosario Fernandez-Fernandez, Alan R Fersht. Atlas Genet Cytogenet Oncol Haematol 2007; Vol 11: 567-573. [Full Text] [PDF] URL : http://atlasgeneticsoncology.org/Genes/S100BID42195ch21q22.html PTGS2 (1q31.1). Panagiotis A Konstantinopoulos, Michalis V Karamouzis, Athanasios G Papavassiliou. Atlas Genet Cytogenet Oncol Haematol 2007; Vol 11: 574-580. [Full Text] [PDF] URL : http://atlasgeneticsoncology.org/Genes/PTGS2ID509ch1q31.html PLCB2 (15q15). Valeria Bertagnolo, Federica Brugnoli, Mascia Benedusi, Silvano Capitani. Atlas Genet Cytogenet Oncol Haematol 2007; Vol 11: 581-587. [Full Text] [PDF] URL : http://atlasgeneticsoncology.org/Genes/PLCB2ID41743ch15q15.html MME (3q25.2). Emina E Torlakovic. Atlas Genet Cytogenet Oncol Haematol 2007; Vol 11: 588-597. [Full Text] [PDF] URL : http://atlasgeneticsoncology.org/Genes/MMEID41386ch3q25.html GRB2 (17q25.1). Gagani Athauda, Donald P Bottaro. Atlas Genet Cytogenet Oncol Haematol 2007; Vol 11: 598-608. [Full Text] [PDF] URL : http://atlasgeneticsoncology.org/Genes/GRB2ID386ch17q25.html CENTG1 (12q14.1). Chan Chi Bun, Ye Keqiang. Atlas Genet Cytogenet Oncol Haematol 2007; 4 II Atlas Genet Cytogenet Oncol Haematol 2007; Vol 11: 609-614. [Full Text] [PDF] URL : http://atlasgeneticsoncology.org/Genes/CENTG1ID44037ch12q14.html CARD8 (19q13.32). Frank A Kruyt. Atlas Genet Cytogenet Oncol Haematol 2007; Vol 11: 615-620. [Full Text] [PDF] URL : http://atlasgeneticsoncology.org/Genes/CARD8ID913ch19q13.html ARHGEF2 (1q22). Valery Poroyko, Anna Birukova. Atlas Genet Cytogenet Oncol Haematol 2007; Vol 11: 621-625. [Full Text] [PDF] URL : http://atlasgeneticsoncology.org/Genes/ARHGEF2ID43150ch1q22.html Leukaemias t(7;9)(q11;p13). Marina Bousquet, Nicole Dastugue, Pierre Brousset. Atlas Genet Cytogenet Oncol Haematol 2007; Vol 11: 626-628. [Full Text] [PDF] URL : http://atlasgeneticsoncology.org/Anomalies/t0709q11p13ID1195.html t(6;8)(q27;p12). José Luis Vizmanos. Atlas Genet Cytogenet Oncol Haematol 2007; Vol 11: 629-634. [Full Text] [PDF] URL : http://atlasgeneticsoncology.org/Anomalies/t68ID1090.html t(5;9)(q33;q22). Berthold Streubel. Atlas Genet Cytogenet Oncol Haematol 2007; Vol 11: 635-638. [Full Text] [PDF] URL : http://atlasgeneticsoncology.org/Anomalies/t0509q33q22ID1458.html T-lineage acute lymphoblastic leukemia (T-ALL). Susana C Raimondi. Atlas Genet Cytogenet Oncol Haematol 2007; Vol 11: 639-660. [Full Text] [PDF] URL : http://atlasgeneticsoncology.org/Anomalies/TALLID1374.html t(9;11)(p22;p15). Cristina Morerio, Claudio Panarello. Atlas Genet Cytogenet Oncol Haematol 2007; Vol 11: 661-663. [Full Text] [PDF] URL : http://atlasgeneticsoncology.org/Anomalies/t0911p22p15ID1232.html Solid Tumours Thyroid: Papillary Carcinoma with inv(7)(q21q34). Raffaele Ciampi, Yuri E. Nikiforov. Atlas Genet Cytogenet Oncol Haematol 2007; Vol 11: 664-667. [Full Text] [PDF] URL : http://atlasgeneticsoncology.org/Tumors/PapilThyrCarcinv7ID5459.html Soft Tissue Tumors: t(X;20)(p11.23;q13.33) in Biphasic Synovial Sarcoma. Clelia Tiziana Storlazzi, Fredrik Mertens. Atlas Genet Cytogenet Oncol Haematol 2007; Vol 11: 668-669. [Full Text] [PDF] URL : http://atlasgeneticsoncology.org/Tumors/SynovialSarcomtX20ID5464.html Soft Tissue Tumors: Aggressive angiomyxoma. Francesca Micci, Petter Brandal. Atlas Genet Cytogenet Oncol Haematol 2007; 4 III Atlas Genet Cytogenet Oncol Haematol 2007; Vol 11: 670-676. [Full Text] [PDF] URL : http://atlasgeneticsoncology.org/Tumors/AggresAngiomyxomaID5203.html Posterior uveal melanoma - updated. Marco Castori, Paola Grammatico. Atlas Genet Cytogenet Oncol Haematol 2007; Vol 11: 677-684. [Full Text] [PDF] URL : http://atlasgeneticsoncology.org/Tumors/UvealmelanomID5047.html Neurofibroma. Lan Kluwe, Christian Hagel, Victor Mautner. Atlas Genet Cytogenet Oncol Haematol 2007; Vol 11: 685-690. [Full Text] [PDF] URL : http://atlasgeneticsoncology.org/Tumors/NeurofibromaID5098.html Head and Neck: Pleomorphic salivary gland adenoma with inv(8)(q12q12) (CHCHD7/PLAG1). Julia Asp, Goran Stenman. Atlas Genet Cytogenet Oncol Haematol 2007; Vol 11: 691-693. [Full Text] [PDF] URL : http://atlasgeneticsoncology.org/Tumors/SalivAdenCHCHD7PLAG1ID5431.html Head and Neck: Pleomorphic salivary gland adenoma with ins(8)(q12;q11q11) (TCEA1- PLAG1). Julia Asp, Goran Stenman. Atlas Genet Cytogenet Oncol Haematol 2007; Vol 11: 694-696. [Full Text] [PDF] URL : http://atlasgeneticsoncology.org/Tumors/SalivAdenTCEA1PLAG1ID5430.html Cancer Prone Diseases Hemihyperplasia isolated. Shubha R Phadke. Atlas Genet Cytogenet Oncol Haematol 2007; Vol 11: 697-699. [Full Text] [PDF] URL : http://atlasgeneticsoncology.org/Kprones/HemihyperplasiaID10046.html Deep Insights Case Reports inv(8)(p11.2q13) found in a patient with chronic myelomonocytic leukemia that progressed to acute myeloid leukemia. Jennifer JS Laffin, Sara J Morrison-Delap, Wayne A Bottner, Eric B Johnson, Patricia Howard- Peebles, Kate J Thompson, Gordana Raca, Karen D Montgomery, Daniel F Kurtycz. Atlas Genet Cytogenet Oncol Haematol 2007; Vol 11: 700-703. [Full Text] [PDF] URL : http://atlasgeneticsoncology.org/Reports/08LaffinID100027.html Educational Items © Atlas of Genetics and Cytogenetics in Oncology and Haematology X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA Home Genes Leukemias Tumors Cancer prone Deep Insight Case Reports Portal Journals Teaching For comments and suggestions or contributions, please contact us [email protected]. Atlas Genet Cytogenet Oncol Haematol 2007; 4 IV Atlas of Genetics and Cytogenetics in Oncology and Haematology WWOX (WW domain containing oxidoreductase) Identity Other names FOR murine name WOX1 Hugo WWOX Location 16q23.1 DNA/RNA Description WWOX is comprised of 9 coding exons in a region of approximately one million base pairs that includes the common fragile site FRA16D. Transcription RT-PCR amplification of Wwox in normal and tumor cDNA samples has shown products apparently originating from alternative transcripts or transcript variants, respectively. Expressed truncated proteins have not been detected. Pseudogene None reported. Protein Atlas Genet Cytogenet Oncol Haematol 2007; 4 499 Alignment of human (hWwox), mouse (Mwwox), fly (fWwox), mosquito (moWwox) and worm (ceWwox) Wwox proteins. The locations of the WW1 and WW2 domains are shown, as well as the predicted sites for nuclear localization, NADP binding, mitochondrial targeting, substrate binding and a proton acceptor. Description WWOX is a 414 amino acid protein that contains two WW domains and a short-chain dehydrogenase/reductase (SDR) domain. Expression WWOX is highly expressed in secretory epithelial cells of reproductive, endocrine and exocrine organs and is expressed in all or most other tissues at a lower level. The protein is not expressed or is expressed at low level in many tumor types, including breast, pancreatic,
Load more

Recommended publications
  • Nuclear and Mitochondrial Genome Defects in Autisms
    UC Irvine UC Irvine Previously Published Works Title Nuclear and mitochondrial genome defects in autisms. Permalink https://escholarship.org/uc/item/8vq3278q Journal Annals of the New York Academy of Sciences, 1151(1) ISSN 0077-8923 Authors Smith, Moyra Spence, M Anne Flodman, Pamela Publication Date 2009 DOI 10.1111/j.1749-6632.2008.03571.x License https://creativecommons.org/licenses/by/4.0/ 4.0 Peer reviewed eScholarship.org Powered by the California Digital Library University of California THE YEAR IN HUMAN AND MEDICAL GENETICS 2009 Nuclear and Mitochondrial Genome Defects in Autisms Moyra Smith, M. Anne Spence, and Pamela Flodman Department of Pediatrics, University of California, Irvine, California In this review we will evaluate evidence that altered gene dosage and structure im- pacts neurodevelopment and neural connectivity through deleterious effects on synap- tic structure and function, and evidence that the latter are key contributors to the risk for autism. We will review information on alterations of structure of mitochondrial DNA and abnormal mitochondrial function in autism and indications that interactions of the nuclear and mitochondrial genomes may play a role in autism pathogenesis. In a final section we will present data derived using Affymetrixtm SNP 6.0 microar- ray analysis of DNA of a number of subjects and parents recruited to our autism spectrum disorders project. We include data on two sets of monozygotic twins. Col- lectively these data provide additional evidence of nuclear and mitochondrial genome imbalance in autism and evidence of specific candidate genes in autism. We present data on dosage changes in genes that map on the X chromosomes and the Y chro- mosome.
    [Show full text]
  • Whole-Genome Microarray Detects Deletions and Loss of Heterozygosity of Chromosome 3 Occurring Exclusively in Metastasizing Uveal Melanoma
    Anatomy and Pathology Whole-Genome Microarray Detects Deletions and Loss of Heterozygosity of Chromosome 3 Occurring Exclusively in Metastasizing Uveal Melanoma Sarah L. Lake,1 Sarah E. Coupland,1 Azzam F. G. Taktak,2 and Bertil E. Damato3 PURPOSE. To detect deletions and loss of heterozygosity of disease is fatal in 92% of patients within 2 years of diagnosis. chromosome 3 in a rare subset of fatal, disomy 3 uveal mela- Clinical and histopathologic risk factors for UM metastasis noma (UM), undetectable by fluorescence in situ hybridization include large basal tumor diameter (LBD), ciliary body involve- (FISH). ment, epithelioid cytomorphology, extracellular matrix peri- ϩ ETHODS odic acid-Schiff-positive (PAS ) loops, and high mitotic M . Multiplex ligation-dependent probe amplification 3,4 5 (MLPA) with the P027 UM assay was performed on formalin- count. Prescher et al. showed that a nonrandom genetic fixed, paraffin-embedded (FFPE) whole tumor sections from 19 change, monosomy 3, correlates strongly with metastatic death, and the correlation has since been confirmed by several disomy 3 metastasizing UMs. Whole-genome microarray analy- 3,6–10 ses using a single-nucleotide polymorphism microarray (aSNP) groups. Consequently, fluorescence in situ hybridization were performed on frozen tissue samples from four fatal dis- (FISH) detection of chromosome 3 using a centromeric probe omy 3 metastasizing UMs and three disomy 3 tumors with Ͼ5 became routine practice for UM prognostication; however, 5% years’ metastasis-free survival. to 20% of disomy 3 UM patients unexpectedly develop metas- tases.11 Attempts have therefore been made to identify the RESULTS. Two metastasizing UMs that had been classified as minimal region(s) of deletion on chromosome 3.12–15 Despite disomy 3 by FISH analysis of a small tumor sample were found these studies, little progress has been made in defining the key on MLPA analysis to show monosomy 3.
    [Show full text]
  • Mouse Germ Line Mutations Due to Retrotransposon Insertions Liane Gagnier1, Victoria P
    Gagnier et al. Mobile DNA (2019) 10:15 https://doi.org/10.1186/s13100-019-0157-4 REVIEW Open Access Mouse germ line mutations due to retrotransposon insertions Liane Gagnier1, Victoria P. Belancio2 and Dixie L. Mager1* Abstract Transposable element (TE) insertions are responsible for a significant fraction of spontaneous germ line mutations reported in inbred mouse strains. This major contribution of TEs to the mutational landscape in mouse contrasts with the situation in human, where their relative contribution as germ line insertional mutagens is much lower. In this focussed review, we provide comprehensive lists of TE-induced mouse mutations, discuss the different TE types involved in these insertional mutations and elaborate on particularly interesting cases. We also discuss differences and similarities between the mutational role of TEs in mice and humans. Keywords: Endogenous retroviruses, Long terminal repeats, Long interspersed elements, Short interspersed elements, Germ line mutation, Inbred mice, Insertional mutagenesis, Transcriptional interference Background promoter and polyadenylation motifs and often a splice The mouse and human genomes harbor similar types of donor site [10, 11]. Sequences of full-length ERVs can TEs that have been discussed in many reviews, to which encode gag, pol and sometimes env, although groups of we refer the reader for more in depth and general infor- LTR retrotransposons with little or no retroviral hom- mation [1–9]. In general, both human and mouse con- ology also exist [6–9]. While not the subject of this re- tain ancient families of DNA transposons, none view, ERV LTRs can often act as cellular enhancers or currently active, which comprise 1–3% of these genomes promoters, creating chimeric transcripts with genes, and as well as many families or groups of retrotransposons, have been implicated in other regulatory functions [11– which have caused all the TE insertional mutations in 13].
    [Show full text]
  • AGAP1 (NM 014914) Human Recombinant Protein Product Data
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for TP314836 AGAP1 (NM_014914) Human Recombinant Protein Product data: Product Type: Recombinant Proteins Description: Recombinant protein of human ArfGAP with GTPase domain, ankyrin repeat and PH domain 1 (AGAP1), transcript variant 2 Species: Human Expression Host: HEK293T Tag: C-Myc/DDK Predicted MW: 88.9 kDa Concentration: >50 ug/mL as determined by microplate BCA method Purity: > 80% as determined by SDS-PAGE and Coomassie blue staining Buffer: 25 mM Tris.HCl, pH 7.3, 100 mM glycine, 10% glycerol Preparation: Recombinant protein was captured through anti-DDK affinity column followed by conventional chromatography steps. Storage: Store at -80°C. Stability: Stable for 12 months from the date of receipt of the product under proper storage and handling conditions. Avoid repeated freeze-thaw cycles. RefSeq: NP_055729 Locus ID: 116987 UniProt ID: Q9UPQ3 RefSeq Size: 4078 Cytogenetics: 2q37.2 RefSeq ORF: 2412 Synonyms: AGAP-1; CENTG2; cnt-g2; GGAP1 Summary: This gene encodes a member of an ADP-ribosylation factor GTPase-activating protein family involved in membrane trafficking and cytoskeleton dynamics. This gene functions as a direct regulator of the adaptor-related protein complex 3 on endosomes. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Oct 2011] This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 2 AGAP1 (NM_014914) Human Recombinant Protein – TP314836 Protein Pathways: Endocytosis Product images: Coomassie blue staining of purified AGAP1 protein (Cat# TP314836).
    [Show full text]
  • Chromosomal Aberrations in Head and Neck Squamous Cell Carcinomas in Norwegian and Sudanese Populations by Array Comparative Genomic Hybridization
    825-843 12/9/08 15:31 Page 825 ONCOLOGY REPORTS 20: 825-843, 2008 825 Chromosomal aberrations in head and neck squamous cell carcinomas in Norwegian and Sudanese populations by array comparative genomic hybridization ERIC ROMAN1,2, LEONARDO A. MEZA-ZEPEDA3, STINE H. KRESSE3, OLA MYKLEBOST3,4, ENDRE N. VASSTRAND2 and SALAH O. IBRAHIM1,2 1Department of Biomedicine, Faculty of Medicine and Dentistry, University of Bergen, Jonas Lies vei 91; 2Department of Oral Sciences - Periodontology, Faculty of Medicine and Dentistry, University of Bergen, Årstadveien 17, 5009 Bergen; 3Department of Tumor Biology, Institute for Cancer Research, Rikshospitalet-Radiumhospitalet Medical Center, Montebello, 0310 Oslo; 4Department of Molecular Biosciences, University of Oslo, Blindernveien 31, 0371 Oslo, Norway Received January 30, 2008; Accepted April 29, 2008 DOI: 10.3892/or_00000080 Abstract. We used microarray-based comparative genomic logical parameters showed little correlation, suggesting an hybridization to explore genome-wide profiles of chromosomal occurrence of gains/losses regardless of ethnic differences and aberrations in 26 samples of head and neck cancers compared clinicopathological status between the patients from the two to their pair-wise normal controls. The samples were obtained countries. Our findings indicate the existence of common from Sudanese (n=11) and Norwegian (n=15) patients. The gene-specific amplifications/deletions in these tumors, findings were correlated with clinicopathological variables. regardless of the source of the samples or attributed We identified the amplification of 41 common chromosomal carcinogenic risk factors. regions (harboring 149 candidate genes) and the deletion of 22 (28 candidate genes). Predominant chromosomal alterations Introduction that were observed included high-level amplification at 1q21 (harboring the S100A gene family) and 11q22 (including Head and neck squamous cell carcinoma (HNSCC), including several MMP family members).
    [Show full text]
  • Screening for Copy Number Variation in Genes Associated with the Long QT Syndrome Clinical Relevance
    Journal of the American College of Cardiology Vol. 57, No. 1, 2011 © 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2010.08.621 Heart Rhythm Disorders Screening for Copy Number Variation in Genes Associated With the Long QT Syndrome Clinical Relevance Julien Barc, PHD,*‡§ François Briec, MD,*†‡§ Sébastien Schmitt, MD,ʈ Florence Kyndt, PharmD, PHD,*‡§ʈ Martine Le Cunff, BS,*‡§ Estelle Baron, BS,*‡§ Claude Vieyres, MD,¶ Frédéric Sacher, MD,# Richard Redon, PHD,*‡§ Cédric Le Caignec, MD, PHD,*‡§ʈ Hervé Le Marec, MD, PHD,*†‡§ Vincent Probst, MD, PHD,*†‡§ Jean-Jacques Schott, PHD*†‡§ Nantes, Angoulême, and Bordeaux, France Objectives The aim of this study was to investigate, in a set of 93 mutation-negative long QT syndrome (LQTS) probands, the frequency of copy number variants (CNVs) in LQTS genes. Background LQTS is an inherited cardiac arrhythmia characterized by a prolonged heart rate–corrected QT (QTc) interval as- sociated with sudden cardiac death. Recent studies suggested the involvement of duplications or deletions in the occurrence of LQTS. However, their frequency remains unknown in LQTS patients. Methods Point mutations in KCNQ1, KCNH2, and SCN5A genes were excluded by denaturing high-performance liquid chromatography or direct sequencing. We applied Multiplex Ligation-dependent Probe Amplification (MLPA) to detect CNVs in exons of these 3 genes. Abnormal exon copy numbers were confirmed by quantitative multiplex PCR of short fluorescent fragment (QMPSF). Array-based comparative genomic hybridization (array CGH) analysis was performed using Agilent Human Genome 244K Microarrays to further map the genomic rearrangements.
    [Show full text]
  • Harnessing Low-Density Lipoprotein Receptor Protein 6 (LRP6) Genetic Variation and Wnt Signaling for Innovative Diagnostics in Complex Diseases
    OPEN The Pharmacogenomics Journal (2018) 18, 351–358 www.nature.com/tpj REVIEW Harnessing low-density lipoprotein receptor protein 6 (LRP6) genetic variation and Wnt signaling for innovative diagnostics in complex diseases Z-M Wang1,2, J-Q Luo1,2, L-Y Xu3, H-H Zhou1,2 and W Zhang1,2 Wnt signaling regulates a broad variety of processes in both embryonic development and various diseases. Recent studies indicated that some genetic variants in Wnt signaling pathway may serve as predictors of diseases. Low-density lipoprotein receptor protein 6 (LRP6) is a Wnt co-receptor with essential functions in the Wnt/β-catenin pathway, and mutations in LRP6 gene are linked to many complex human diseases, including metabolic syndrome, cancer, Alzheimer’s disease and osteoporosis. Therefore, we focus on the role of LRP6 genetic polymorphisms and Wnt signaling in complex diseases, and the mechanisms from mouse models and cell lines. It is also highly anticipated that LRP6 variants will be applied clinically in the future. The brief review provided here could be a useful resource for future research and may contribute to a more accurate diagnosis in complex diseases. The Pharmacogenomics Journal (2018) 18, 351–358; doi:10.1038/tpj.2017.28; published online 11 July 2017 INTRODUCTION signaling pathways and expressed in various target organs.1 LDLR- The Wnt1 gene was identified in 1982. Ensuing studies in related proteins 5/6 (LRP5/6) belong to this large family and Drosophila and Xenopus unveiled a highly conserved Wnt/ function as co-receptors of the Wnt/β-catenin pathway. These β-catenin pathway, namely, canonical Wnt signaling.
    [Show full text]
  • Defining Functional Interactions During Biogenesis of Epithelial Junctions
    ARTICLE Received 11 Dec 2015 | Accepted 13 Oct 2016 | Published 6 Dec 2016 | Updated 5 Jan 2017 DOI: 10.1038/ncomms13542 OPEN Defining functional interactions during biogenesis of epithelial junctions J.C. Erasmus1,*, S. Bruche1,*,w, L. Pizarro1,2,*, N. Maimari1,3,*, T. Poggioli1,w, C. Tomlinson4,J.Lees5, I. Zalivina1,w, A. Wheeler1,w, A. Alberts6, A. Russo2 & V.M.M. Braga1 In spite of extensive recent progress, a comprehensive understanding of how actin cytoskeleton remodelling supports stable junctions remains to be established. Here we design a platform that integrates actin functions with optimized phenotypic clustering and identify new cytoskeletal proteins, their functional hierarchy and pathways that modulate E-cadherin adhesion. Depletion of EEF1A, an actin bundling protein, increases E-cadherin levels at junctions without a corresponding reinforcement of cell–cell contacts. This unexpected result reflects a more dynamic and mobile junctional actin in EEF1A-depleted cells. A partner for EEF1A in cadherin contact maintenance is the formin DIAPH2, which interacts with EEF1A. In contrast, depletion of either the endocytic regulator TRIP10 or the Rho GTPase activator VAV2 reduces E-cadherin levels at junctions. TRIP10 binds to and requires VAV2 function for its junctional localization. Overall, we present new conceptual insights on junction stabilization, which integrate known and novel pathways with impact for epithelial morphogenesis, homeostasis and diseases. 1 National Heart and Lung Institute, Faculty of Medicine, Imperial College London, London SW7 2AZ, UK. 2 Computing Department, Imperial College London, London SW7 2AZ, UK. 3 Bioengineering Department, Faculty of Engineering, Imperial College London, London SW7 2AZ, UK. 4 Department of Surgery & Cancer, Faculty of Medicine, Imperial College London, London SW7 2AZ, UK.
    [Show full text]
  • Lgr5 Homologues Associate with Wnt Receptors and Mediate R-Spondin Signalling
    ARTICLE doi:10.1038/nature10337 Lgr5 homologues associate with Wnt receptors and mediate R-spondin signalling Wim de Lau1*, Nick Barker1{*, Teck Y. Low2, Bon-Kyoung Koo1, Vivian S. W. Li1, Hans Teunissen1, Pekka Kujala3, Andrea Haegebarth1{, Peter J. Peters3, Marc van de Wetering1, Daniel E. Stange1, Johan E. van Es1, Daniele Guardavaccaro1, Richard B. M. Schasfoort4, Yasuaki Mohri5, Katsuhiko Nishimori5, Shabaz Mohammed2, Albert J. R. Heck2 & Hans Clevers1 The adult stem cell marker Lgr5 and its relative Lgr4 are often co-expressed in Wnt-driven proliferative compartments. We find that conditional deletion of both genes in the mouse gut impairs Wnt target gene expression and results in the rapid demise of intestinal crypts, thus phenocopying Wnt pathway inhibition. Mass spectrometry demonstrates that Lgr4 and Lgr5 associate with the Frizzled/Lrp Wnt receptor complex. Each of the four R-spondins, secreted Wnt pathway agonists, can bind to Lgr4, -5 and -6. In HEK293 cells, RSPO1 enhances canonical WNT signals initiated by WNT3A. Removal of LGR4 does not affect WNT3A signalling, but abrogates the RSPO1-mediated signal enhancement, a phenomenon rescued by re-expression of LGR4, -5 or -6. Genetic deletion of Lgr4/5 in mouse intestinal crypt cultures phenocopies withdrawal of Rspo1 and can be rescued by Wnt pathway activation. Lgr5 homologues are facultative Wnt receptor components that mediate Wnt signal enhancement by soluble R-spondin proteins. These results will guide future studies towards the application of R-spondins for regenerative purposes of tissues expressing Lgr5 homologues. The genes Lgr4, Lgr5 and Lgr6 encode orphan 7-transmembrane 4–5 post-induction onwards.
    [Show full text]
  • EML4-ALK Variants: Biological and Molecular Properties, and the Implications for Patients
    cancers Review EML4-ALK Variants: Biological and Molecular Properties, and the Implications for Patients Sarah R. Sabir ID , Sharon Yeoh, George Jackson and Richard Bayliss * ID Astbury Centre for Structural Molecular Biology, School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds LS2 9JT, UK; [email protected] (S.R.S.); [email protected] (S.Y.); [email protected] (G.J.) * Correspondence: [email protected]; Tel.: +44-113-343-9919 Academic Editor: Raymond Lai Received: 9 August 2017; Accepted: 31 August 2017; Published: 5 September 2017 Abstract: Since the discovery of the fusion between EML4 (echinoderm microtubule associated protein-like 4) and ALK (anaplastic lymphoma kinase), EML4-ALK, in lung adenocarcinomas in 2007, and the subsequent identification of at least 15 different variants in lung cancers, there has been a revolution in molecular-targeted therapy that has transformed the outlook for these patients. Our recent focus has been on understanding how and why the expression of particular variants can affect biological and molecular properties of cancer cells, as well as identifying the key signalling pathways triggered, as a result. In the clinical setting, this understanding led to the discovery that the type of variant influences the response of patients to ALK therapy. Here, we discuss what we know so far about the EML4-ALK variants in molecular signalling pathways and what questions remain to be answered. In the longer term, this analysis may uncover ways to specifically treat patients for a better outcome. Keywords: anaplastic lymphoma kinase; echinoderm microtubule-associated protein; non-small cell lung cancer; tyrosine kinase inhibitor 1.
    [Show full text]
  • | Hai Lala at Matalamitaka Huoleht I
    |HAI LALA AT MATALAMITAKAUS009816096B2 HUOLEHT I (12 ) United States Patent (10 ) Patent No. : US 9 ,816 , 096 B2 Heintz et al. (45 ) Date of Patent: Nov . 14 , 2017 ( 54 ) METHODS AND COMPOSITIONS FOR 6 , 143 , 566 A 11/ 2000 Heintz et al. TRANSLATIONAL PROFILING AND 6 , 156 , 574 A 12 / 2000 Heintz et al. 6 , 252 , 130 B1 6 / 2001 Federoff MOLECULAR PHENOTYPING 6 , 270, 969 B1 8 / 2001 Hartley et al. 6 , 403 ,374 B1 6 / 2002 Tsien et al. (71 ) Applicant: THE ROCKEFELLER 6 , 410 , 317 B1 6 /2002 Farmer UNIVERSITY , New York , NY (US ) 6 , 441 , 269 B1 8 / 2002 Serafini et al . 6 , 485 , 912 B1 11/ 2002 Heintz et al. @ 6 , 495 , 318 B2 12 / 2002 Harney ( 72 ) Inventors: Nathaniel Heintz , Pelham Manor, NY 6 ,635 ,422 B2 10 / 2003 Keene et al. (US ) ; Paul Greengard , New York , NY 6 , 821, 759 B1 11/ 2004 Heintz et al . (US ) ; Myriam Heiman , New York , NY 7 , 098, 031 B2B2 8 /2006 Choulika et al . (US ) ; Anne Schaefer , New York , NY 7 ,297 ,482 B2 11 /2007 Anderson et al . (US ) ; Joseph P . Doyle , New York , NY 7 , 393 , 632 B2 7 / 2008 Cheo et al. 2003 /0119104 A1 6 /2003 Perkins et al . (US ) ; Joseph D . Dougherty , St. Louis , 2004 / 0023256 A1 2 / 2004 Puglisi et al . MO (US ) 2005 / 0009028 Al 1 /2005 Heintz et al. 2006 /0183147 AL 8 /2006 Meyer - Franke (73 ) Assignee : THE ROCKEFELLER 2011/ 0314565 Al 12 /2011 Heintz et al . UNIVERSITY , New York , NY (US ) FOREIGN PATENT DOCUMENTS ( * ) Notice : Subject to any disclaimer , the term of this patent is extended or adjusted under 35 EP 1132479 A1 9 / 2001 WO WO -01 / 48480 A1 7 /2001 U .
    [Show full text]
  • High-Grade Glioneuronal Tumor with an ARHGEF2–NTRK1 Fusion Gene
    Brain Tumor Pathology (2019) 36:121–128 https://doi.org/10.1007/s10014-019-00345-y CASE REPORT High‑grade glioneuronal tumor with an ARHGEF2–NTRK1 fusion gene Kazuhiko Kurozumi1 · Yoshiko Nakano2 · Joji Ishida1 · Takehiro Tanaka3 · Masatomo Doi4 · Junko Hirato5 · Akihiko Yoshida6 · Kana Washio7 · Akira Shimada7 · Takashi Kohno8 · Koichi Ichimura2 · Hiroyuki Yanai9 · Isao Date1 Received: 1 March 2019 / Accepted: 20 March 2019 / Published online: 22 April 2019 © The Japan Society of Brain Tumor Pathology 2019 Abstract Here, we report a highly unusual case of high-grade glioneuronal tumor with a neurotrophic tropomyosin receptor kinase (NTRK) fusion gene. A 13-year-old girl presented with headache and vomiting and MRI detected two cystic lesions bilaterally in the frontal areas with surrounding edema. The left larger tumor was removed by left frontal craniotomy. The tumor was diagnosed as a high-grade glioneuronal tumor, unclassifed. Methylation profling classifed it as a difuse leptomeningeal glioneuronal tumor (DLGNT) with low confdence. This tumor showed genotypes frequently found in DLGNT such as 1p/19q codeletion without IDH mutation and, however, did not have the typical DLGNT clinical and histological features. RNA sequencing identifed an ARHGEF2 (encoding Rho/Rac guanine nucleotide exchange factor 2)–NTRK1 fusion gene. The presence of recurrent NTRK fusion in glioneuronal tumors has an important implication in the clinical decision making and opens up a possibility of novel targeted therapy. Keywords Pediatric brain tumor · 1p19qLOH · RNA sequencing · NTRK1 Introduction diagnosis of glioneuronal tumors has been sometimes chal- lenging. However, unique molecular signatures have recently Mixed glioneuronal tumors are rare group of brain tumors been identifed, enabling creation of classifcation schemes that consist of glial and neuronal components.
    [Show full text]